Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint

UBS downgraded Acadia Pharmaceuticals (ACAD) from Buy to Neutral, lowering its price target from $49.00 to $23.00. The company's stock is currently trading at $18.62, with a GF Value™ of $25.90, suggesting it is 28.1% undervalued. Insider sales totaled $1,019,973 over the past three months, and the company has a GF Score™ of 79/100.

RBC Capital maintained its Outperform rating on Acadia Pharmaceuticals (NASDAQ:ACAD) with a $37.00 price target, citing attractive valuation and reduced risk around Nuplazid revenue. The stock trades at $20.08 with a P/E ratio of 9.09 and PEG ratio of 0.14. Analysts revised earnings upwards, but recent Phase 2 trial results missed primary endpoint, leading to adjusted price targets.

H.C. Wainwright lowered its price target on Acadia Pharmaceuticals (ACAD) to $33 from $37, citing a Phase 2 trial miss. The stock fell 22% to $20.68. Despite this, some analysts see value, with price targets up to $49. The trial missed its primary endpoint but hit a key secondary endpoint.

Acadia Pharmaceuticals (ACAD) stock fell 5% after analysts cut price targets following Phase 2 RADIANT trial results for Remlifanserin in Alzheimer's disease psychosis. The trial missed the primary endpoint but showed promise in a subgroup. Analysts from Needham, Deutsche Bank, BMO Capital, and Citizens lowered targets but maintained positive ratings, citing future potential.

ACADIA Pharmaceuticals (ACAD) shares fell 13% after Goldman Sachs initiated a 'sell' rating and $17 price target due to weak phase 2 trial results for remlifanserin. Citi and BMO Capital maintained positive ratings but lowered price targets. The company plans to present detailed results at an upcoming conference. Hedge funds increased holdings in Q2, with 38 funds holding positions.

Acadia reported Phase 2 topline results for remlifanserin in Alzheimer’s disease psychosis. The 60 mg dose showed nominal significance on CGI-S, while the 30 mg dose showed minimal improvement. The company will proceed with Phase 3 studies, presenting detailed data at CTAD 2026. Safety profile was favorable. (ACAD)